Zentalis Pharmaceuticals (NASDAQ:ZNTL) Earns “Buy” Rating from HC Wainwright

Zentalis Pharmaceuticals (NASDAQ:ZNTL)‘s stock had its “buy” rating reaffirmed by equities researchers at HC Wainwright in a research note issued to investors on Friday,Benzinga reports. They presently have a $20.00 target price on the stock. HC Wainwright’s price target would suggest a potential upside of 406.33% from the company’s previous close.

A number of other brokerages have also recently commented on ZNTL. Wedbush raised Zentalis Pharmaceuticals from an “underperform” rating to a “neutral” rating and set a $4.00 price target for the company in a research report on Monday, August 12th. Oppenheimer restated an “outperform” rating and set a $20.00 target price on shares of Zentalis Pharmaceuticals in a research report on Monday, September 16th. Five research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Zentalis Pharmaceuticals currently has a consensus rating of “Hold” and an average target price of $10.25.

Zentalis Pharmaceuticals Trading Up 0.8 %

NASDAQ ZNTL opened at $3.95 on Friday. The firm’s fifty day simple moving average is $3.41 and its two-hundred day simple moving average is $5.52. The firm has a market capitalization of $281.48 million, a P/E ratio of -1.59 and a beta of 1.74. Zentalis Pharmaceuticals has a 12-month low of $2.66 and a 12-month high of $18.07.

Institutional Investors Weigh In On Zentalis Pharmaceuticals

Several large investors have recently bought and sold shares of ZNTL. ProShare Advisors LLC raised its position in shares of Zentalis Pharmaceuticals by 9.0% in the first quarter. ProShare Advisors LLC now owns 15,436 shares of the company’s stock valued at $243,000 after buying an additional 1,274 shares during the last quarter. Price T Rowe Associates Inc. MD increased its holdings in shares of Zentalis Pharmaceuticals by 20.2% in the first quarter. Price T Rowe Associates Inc. MD now owns 3,489,709 shares of the company’s stock valued at $54,999,000 after purchasing an additional 585,644 shares during the last quarter. Kennedy Capital Management LLC purchased a new position in Zentalis Pharmaceuticals during the first quarter worth approximately $189,000. Opaleye Management Inc. acquired a new position in Zentalis Pharmaceuticals during the first quarter worth $3,152,000. Finally, SG Americas Securities LLC purchased a new stake in Zentalis Pharmaceuticals in the 2nd quarter valued at $58,000.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.